You're reading the brief from Fri, Oct 9.Back to the latest brief
Fri, Oct 9
5 itemsThis week's digest is led by a Phase 3 failure for Argenx's Vyvgart in Sjögren's disease and an FDA safety signal after four deaths in a schizophrenia drug trial. Other notable items include a major review favoring nicotine e-cigarettes for quitting, preclinical progress on osteoarthritis and lymphoma, and an FDA request for input on ibogaine trials.
Argenx's Vyvgart fails Phase 3 trial in Sjögren's disease
Argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial in patients with Sjögren's disease, a chronic autoimmune disorder. STAT called the result an unusual setback.
Why it mattersVyvgart is a key growth driver for Argenx, so a late-stage miss in a new autoimmune indication may reshape expectations for the drug's expansion.
Review of 80 trials finds nicotine e-cigarettes aid quitting
A major review of 80 clinical trials found nicotine e-cigarettes helped more smokers quit than patches, gum and several other common approaches. Researchers said regulated vaping is not risk-free but may be less harmful than continued smoking.
Why it mattersThis evidence could influence clinical quit-smoking guidance and how regulators weigh vaping products as a harm-reduction tool.
Stanford molecule turns lymphoma protein into cancer kill switch
A Stanford-designed molecule turns a major lymphoma-promoting protein against cancer cells, activating their self-destruct machinery. In mice, it completely eliminated aggressive human lymphoma tumors within 11 days, though much more testing is needed.
Why it mattersA new mechanism that kills tumors rather than just blocking growth could open a route to therapies for aggressive lymphomas.
Epilepsy drug lacosamide shows promise against osteoarthritis in preclinical work
Yale researchers found the FDA-approved epilepsy drug lacosamide appears to block a protein involved in pain signaling and cartilage destruction, helping damaged joints shift toward repair in preclinical studies.
Why it mattersIf it holds up in humans, an already-approved drug could be repurposed to do more than ease osteoarthritis pain.
FDA seeks public input on early-phase ibogaine trials
The FDA announced a request for information describing approaches it is considering for the design of early-phase clinical trials of ibogaine drug products and is seeking public input.
Why it mattersThe request signals the agency is weighing a path for studying a psychedelic-linked compound with known cardiac risks.